Statins: Intervention studies facts and perspectives;Statines: Études d'intervention, faits et perspectives

Annales d'Endocrinologie

Volumn 62, Issue 2, 2001, Pages 133-144

  Durlach, V ^a  

^a Svc d'Endocrinol Maladies Metab   (France)

Author keywords

Clinical trials; HMG CoA reductase inhibitors; Statins; Unanswered questions

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NIFEDIPINE; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DISEASE; MORBIDITY; MORTALITY; OSTEOPOROSIS; PLEIOTROPY; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 0035099997     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Prevention of coronary heart disease with pravastatine in men with hypercholesterolemia
2. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis program
5. The effect of pravastatine on coronary events after myocardial infarction in patients with average cholesterol levels
6. Long turn intervention with pravastatine in ischaemic disease. Prevention of cardio-vascular events and death with pravastatin in patients with coronary heart disease and proad rangue of initial cholesterol level
7. Modification of coronary artery disease progression by cholesterol-lowering therapy: The angiographic studies
8. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression
9. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary heart disease as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial (CCAIT)
10. Effects of Simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS)
11. The effects of Simvastatin on progression of coronary heart disease (CIS)
12. Mode ultrasound assessment of pravastatine treatment effect on carotid and femoryl artery walls and its correlations with coronary arteriographic findings: A report of the regression growth evaluation statin study
13. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. PLAC I investigation
14. Effects of Fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations
15. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
16. The effect of aggressive lowering of low density lipoprotein cholesterol-level and low dose anticoagulation on obstructive changes in saveinous-vein coronary by-pass grafts
17. Effect of HMG CoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials
18. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials
19. Pravastatin therapy and the risk of stroke
20. Cœur et diabète
21. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with or without prior infarction
22. Quelle place pour l'association statine-fibrate dans le traitement des hyperlipidémies
23. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen male study
24. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
25. Comparison of statins in hypertriglyceridemia
26. Effects of statins on triglyceride metabolisme
27. Guide to preventive cardiology for women
28. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
29. For the Atorvastatin Versus Revascularization Treatment (AVERT) Investigators